Therapy Areas: Vaccines
Takeda Pharmaceutical to import and distribute 50 million doses of Moderna's COVID-19 vaccine in Japan
29 October 2020 -

Takeda Pharmaceutical Co (Takeda), a Japanese multinational pharmaceutical and biopharmaceutical company, has said it would import and distribute 50 million doses of Moderna Inc's COVID-19 vaccine candidate in Japan, Reuter news agency reported on Thursday.

Under this deal, Takeda will be responsible for securing regulatory approval for the vaccine, known as mRNA-1273, with supply starting in the first half of 2021, Takeda said in a release.

Reportedly, the companies were previously in talks to supply 40 million or more doses of the vaccine in Japan.

Moderna's candidate is in late-stage trials in the US.

Also, Takeda has agreed to produce Novavax Inc's COVID-19 vaccine, aiming to make 250 million doses for use in Japan.